Convergence Technology 1
AI & Bio
The CT1 research group develops integrated AI-driven platforms to accelerate the discovery and design of therapeutics for aging-related diseases. By combining deep learning, generative models, molecular dynamics, reinforcement learning, and quantum simulations with structural biology techniques such as Cryo-EM, the group enables high-precision prediction of drug–protein interactions and rapid optimization of lead compounds. CT1 also builds virtual cell and virtual microbiome models based on single-cell omics to analyze gene networks, predict perturbation effects, and identify actionable biomarkers and therapeutic targets. Through AI–experiment feedback loops and advanced delivery and targeting strategies, the group drives next-generation drug discovery and precision medicine for aging interventions.
Interdisciplinary research with other groups
The CT1–CR1–CR3 convergent research strategy integrates AI-driven drug discovery with basic aging research to accelerate the development of innovative therapeutics for major aging-related diseases, including neurological, immune, infectious, metabolic, and cancer disorders. By leveraging novel drug target information generated by the CR1–CR3 aging research groups, the program enhances candidate discovery and translation through a multi-layered platform that combines AI-based high-throughput and virtual screening, generative drug library design, and ultra-fast lead identification. Advanced AI–MD–RL simulations, cryo-EM–informed structural prediction, and quantum simulation–based drug design are employed to precisely model and optimize drug–target interactions, while human protein binder libraries further refine precision drug design. In parallel, virtual cell, virtual biome, and pan-genome–based biological systems are used to analyze aging biomarkers and gene networks, enabling improved disease prediction and the development of personalized therapies for aging-related conditions.
Investigators
Wan Namkung
Research group leader
Structure-Based Drug Discovery for Aging-Related Proteins
